{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=21",
    "query": {
      "intervention": "therapy",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 83839,
    "total_pages": 8384,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T12:23:37.879Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01517984",
      "title": "Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Tacrolimus (CNI) Withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Standard Immunosuppressive Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2010-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517984"
    },
    {
      "nct_id": "NCT00006184",
      "title": "Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Myeloma Immunoglobulin Idiotype Vaccine",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "GMCSF (granulocyte macrophage colony stimulating factor)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GCSF (granulocyte colony stimulating factor)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2001-02-08",
      "completion_date": "2008-01-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-20",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006184"
    },
    {
      "nct_id": "NCT01182506",
      "title": "Rehabilitation of Cognitive Changes in Breast Cancer Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cogmed Working Memory Training Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 69 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2010-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182506"
    },
    {
      "nct_id": "NCT00134706",
      "title": "A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2009-12-09",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Dover, New Hampshire + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        },
        {
          "city": "Dover",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134706"
    },
    {
      "nct_id": "NCT00563784",
      "title": "TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2007-11",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00563784"
    },
    {
      "nct_id": "NCT00130637",
      "title": "Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anterior Uveitis",
        "Arthritis, Juvenile Idiopathic",
        "Iritis",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 6,
      "start_date": "2005-08",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130637"
    },
    {
      "nct_id": "NCT02598895",
      "title": "Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "PSA Progression",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2016-01-26",
      "completion_date": "2021-09-14",
      "has_results": true,
      "last_update_posted_date": "2022-11-17",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598895"
    },
    {
      "nct_id": "NCT06656637",
      "title": "To Drill or Not to Drill: Do Memory Drills Help Train the Ability to \"Remember to Remember\" in Veterans",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Memory Deficit"
      ],
      "interventions": [
        {
          "name": "Memory Drilling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Compensatory Strategies",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Processing Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2024-10-22",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06656637"
    },
    {
      "nct_id": "NCT03034772",
      "title": "Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Dorzolamide-timolol",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-02-08",
      "completion_date": "2019-07-05",
      "has_results": true,
      "last_update_posted_date": "2020-06-19",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03034772"
    },
    {
      "nct_id": "NCT03363945",
      "title": "Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "MDR-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medeor Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-03-15",
      "completion_date": "2024-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-21T12:23:37.879Z",
      "location_count": 18,
      "location_summary": "Loma Linda, California • Los Angeles, California • Stanford, California + 15 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363945"
    }
  ]
}